Should end-of-therapy echocardiograms be obtained for AYA patients with sarcomas who have received high-dose anthracyclines?

Exposure to anthracyclines will predispose cancer survivors to cardiomyopathy in a dose dependent manner, both alone and in combination with radiation therapy to the chest. While cumulative doses > 250 mg/m2 are associated with increasing risk of cardiomyopathy, lower doses have been implicated as well, thus there is no definitively "safe" value that is associated with zero increased risk. The Children's Oncology Group (COG) Long Term Follow Up Guidelines and National Comprehensive Cancer Networ...